Inhibition of rat small-intestinal alpha-(1 leads to 2)-fucosyltransferase

Recognition of synthetic analogues of the acceptor, beta-D-Gal p-OR, by the blood-group H gene-specified glycosyltransferase

The acceptor-substrate specificity of a cloned alpha-(1-->2) fucosyltransferase has been explored using structural analogues of octyl beta-D-galactopyranoside (4). This monosaccharide is the minimum acceptor-substrate for the H-transferase, one of two enzymes responsible for the biosynthesis of the O blood-group antigen, which terminates in the sequence alpha-L-Fuc p-(1-->2)-beta-D-Galp. Galactoside 4 has a Km of 6 mM with this enzyme. Eighteen analogues of 4 have been prepared, including those where the hydroxyl groups at C-3, C-4, and C-6 have been replaced, independently, with deoxy, fluoro, O-methyl, amino, and acetamido functionalities. The C-3 and C-4 epimers have been prepared as has the C-5 de(hydroxymethyl)ated derivative. These compounds were screened as potential acceptors and inhibitors of the fucosyltransferase. The C-6 analogues that do not possess a charge show substrate activity with relative rates in the range of 27-316% that of 4. The C-3 modified analogues are inhibitors with estimated Ki values of 0.9-43 mM. Those analogues with modifications at C-4 were both poor inhibitors and acceptors.

Mucin biosynthesis. Enzymic properties of human-tracheal epithelial GDP-L-fucose:beta-D-galactoside alpha-(1----2)-L-fucosyltransferase

The human-tracheal, epithelial alpha-(1----2)-L-fucosyltransferase that transfers L-fucose from GDP-L-fucose to an acceptor containing a beta-D-galactopyranosyl group at the nonreducing terminal was characterized. Optimal enzyme activity was obtained at pH 6.5. 20-30mM MnCl2 (or CaCl2), and 0.05% Triton X-100 or 0.5% Tween 20. Mg2+ and Ba2+ ions moderately enhanced the enzyme activity, whereas Fe2+, Co2+, Zn2+, and Cd2+ ions were inhibitory. The enzyme activity was inhibited by N-ethylmaleimide and nucleotides of guanine, inosine, xanthine, and uridine. However, ATP and dithiothreitol did not affect the enzyme activity. The apparent Michaelis constant for GDP-L-fucose, freezing point-depressing glycoproteins (expressed as Gal----GalNAc----Thr), and phenyl beta-D-galactopyranoside was 0.29, 5.70, and 25.4mM, respectively. Under alkali-borohydride conditions (0.05M NaOH-M NaBH4, 45 degrees, 20 h), an L-[14C]fucosyltrisaccharide was released from the product obtained by use of freezing point-depressing glycoprotein as the acceptor. The alpha-L anomeric configuration of the fucoside was determined by the release of L-[14C]fucose from the purified trisaccharide by Turbo cornutus alpha-L-fucosidase. The (1----2) linkage of the L-fucosyl group to the D-galactosyl residue was established by methylation technique (m.s.-g.l.c.). The present enzyme has properties similar to those of the human milk alpha-(1----2)-L-fucosyltransferase which is encoded by a secretor gene.

Glycosyltransferases of the human cervical epithelium. I. Characterization of a beta-galactoside alpha-2-L-fucosyltransferase and the identification of a beta-N-acetylglucosaminide alpha-3-L-fucosyltransferase

Using phenyl beta-D-galactoside as an acceptor, alpha-2-L-fucosyltransferase activity was identified in human cervical epithelium with pH optima at 6.0 and 7.2. The different response to p-chloromercuribenzoate, and ability to utilise asialofetuin as an acceptor, suggests the presence of two fucosyltransferases. The acid form is probably involved in glycoprotein synthesis in vivo. At pH 6.0, fucosyltransferase has a temperature optimum of 25 degrees C, requires the presence of Triton X-100 and either manganese or magnesium for maximal activity, and has Km values for GDP-L-[14-C]fucose and phenyl beta-D-galactoside of 32.1 . 10(-6) M and 8.2 . 10(-3) M, respectively. Guanosine nucleotides are potent inhibitors of the fucosyltransferase reaction; GDP is a competitive inhibitor while, depending on its concentration, GTP can either inhibit or activate the reaction. The alpha-L-fucosidase present in cervical tissue has negligible activity towards the enzyme product, phenyl-alpha-2-L-[14C]fucosyl-beta-D-galactoside. The use of high and low molecular weight acceptors indicates the presence of a beta-N-acetylglucosaminide alpha-3-L-fucosyltransferase and an N-acetylgalactosaminide fucosyltransferase.

Regulation of rat-liver glycoprotein: N-acetylneuraminic acid transferase activity by pyrimidine nucleotides

CMP-N-acetylneuraminic acid: glycoprotein sialyltransferase activities were assayed in rat liver microsomal fractions using desialylated fetuin as the substrate acceptors for N-acetylneuraminic acid. It was found that cytidine nucleotides specifically depressed enzyme activities. CMP was shown to act as a competitive inhibitor with an apparent Ki of 0.62 mM. N-Acetylneuraminic acid at 1.15 mM had no effect on enzyme activities. Uridine nucleotides at 1.15 mM, especially UDP, increased enzyme activities. UDP may act as an allosteric activating agent increasing the apparent V. Other nucleotides, sugars and nucleotide-sugars at similar concentrations affected sialyltransferase activities only slightly. A general mechanism is proposed for the regulation of glycosyltransferase activities by free nucleotides.

Glycosyltransferases in human blood.I. Galactosyltransferase in human serum and erythrocyte membranes

Human serum and hemoglobin-free erythrocyte membranes were found to contain a galactosyltransferase which catalyzes the transfer of galactose from UDP-galactose to specific large and small molecular weight acceptors. The requirements for enzyme activity were found to be similar for the enzymes from both sources. However, the membrane-bound enzyme depended on a detergent for maximal activity. Mn(++) was an absolute requirement for transfer and uridine nucleoside phosphates were inhibitors. The most effective acceptor for galactose was a glycoprotein containing N-acetylglucosamine residues in the terminal position of its oligosaccharide side chains, N-acetylglucosamine was also an acceptor. While the presence of alpha-lactalbumin in the incubation medium resulted in a significant decrease in the transfer of galactose to N-acetylglucosamine, glucose, which was not an acceptor for galactose in the absence of alpha-lactalbumin, became an excellent acceptor. The serum enzyme catalyzed the transfer of 54 nmoles of galactose per milliliter of serum per hour and its apparent K(m) for UDP-galactose was 7.5 x 10(-6)M. The membrane enzyme had a similar apparent K(m). Using a quantitative assay system the enzyme was found to be present in all individuals studied, regardless of their blood type, secretor status, or sex.

Glycosyltransferases in human blood. II. Study of serum galactosyltransferase and N-acetylgalactosaminyltransferase in patients with liver diseases

Serum galactosyltransferase activity was found to be elevated in patients with alcoholic and other liver disorders but remained at a normal level in patients with a variety of nonhepatic diseases. The properties of the galactosyltransferase in patients with liver disease were compared with those of the enzyme in the serum of normal subjects. The possible presence of inhibitors or activators in the serum was examined. Results indicated that in patients with liver disease, the rise in the serum galactosyltransferase was due to an increase in the level of the enzyme present in normal serum and not due to the appearance of a new enzyme. In the cases examined, the level of the enzyme increased with the deterioration of liver function and declined in a patient recovering from acute alcoholic hepatitis. Another glycosyltransferase, an N-acetylgalactosaminyltransferase, was not elevated in the serum of liver disease patients and, unlike the galactosyltransferase, was not detected in normal liver. The results suggest that the serum galactosyltransferase originates from the liver and that an abnormal rise in the level of this enzyme in serum is due to hepatocellular damage.